--- title: "Hexarelin: Dosing & Vendor Prices | BodyHackGuide" url: https://www.bodyhackguide.co/compound/hexarelin description: "Hexarelin: dosing protocols, mechanism & side effects, 14 PubMed results. Compare current vendor prices." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Image: Hexarelin molecular structure (https://www.bodyhackguide.co/assets/peptide-structure-placeholder-DUmZBF_j.png) # Hexarelin Growth Hormone / IGF-1 Axis (https://www.bodyhackguide.co/wiki#cat-growth-hormone-/-igf-1-axis)Phase 2 Also known as: Examorelin Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. It is structurally similar to GHRP-6 and GHRP-2 but features a 2-methyl-substituted tryptophan residue that produces significantly higher GH-releasing potency on a per-molecule basis — reportedly the most potent of the classical GHRPs when measured by peak GH pulse amplitude at equivalent molar doses ([Imbimbo et al., 1994]). This potency comes with a tradeoff: hexarelin produces the most pronounced cortisol, prolactin, and ACTH elevations of any commonly-used GHS compound. Price check No vendor listings yet We do not track a vendor for Hexarelin yet. Compare other compounds: https://www.bodyhackguide.co/compare Half-life: ~55 minutes (IV, per Imbimbo 1994) Route: Subcutaneous, Intramuscular MW: 887 Da CAS: 140703-51-1 14 PubMed results (https://pubmed.ncbi.nlm.nih.gov/?term=hexarelin%20growth%20hormone%20secretagogue%20cardiac) Last reviewed: May 4, 2026 ## Overview ### At A Glance Mechanism Dual Receptor Pharmacology… Half-Life ~55 minutes (IV, per Imbimbo 1994) Dosing 1–2 times daily; subject to desensitization within 4 weeks Dose Range 100–200 mcg per injection Routes Subcutaneous Intramuscular Common Vials 2mg 5mg Potential Benefits Maximum GH output Cardiac protection Muscle building Body composition Recovery Safety Notes Common Cortisol and prolactin elevation Water retention Fatigue Hunger ### Mechanism of Action ### Dual Receptor Pharmacology Hexarelin is distinguished from other GHRPs by its activity at **two distinct receptors**: #### GHS-R1a (primary - GH release) Like all GHRPs, hexarelin binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons: 1. **Gq/11 coupling** phospholipase C IP3/Ca release GH granule exocytosis 2. **Hypothalamic arcuate nucleus activation** endogenous GHRH amplification 3. **Partial somatostatin antagonism** removes the GH-release ceiling The GH-release potency of hexarelin exceeds GHRP-2 and GHRP-6 at equivalent molar doses. Peak GH elevations of ~50-70 ng/mL are achievable with modest (1-2 mcg/kg) IV bolus doses. #### CD36 (secondary - cardioprotective) Hexarelin also binds **CD36** - a scavenger receptor expressed on cardiomyocytes, macrophages, and vascular endothelium. CD36 binding is not a property of GHRP-2 or ipamorelin; it is a distinctive hexarelin feature and drives the cardioprotective effects: - **Reduced infarct size** in experimental ischemia-reperfusion ([Torsello 2003]) - **Improved ventricular contractility** in cardiomyopathy models - **Anti-inflammatory effects** at vascular endothelium - **Favorable cardiac remodeling** following experimental MI The CD36 pathway is mechanistically independent of the GH/IGF-1 axis - hexarelin produces cardiac protection even when co-administered with GHS-R1a antagonists that block the GH-release signal. This has generated ongoing research interest in ghrelin-agonist cardioprotection as a discrete therapeutic avenue. ### HPA Axis Cross-Reactivity (The Cost of Potency) The 2-methyl-tryptophan modification that amplifies GH-release potency also amplifies binding at pituitary corticotroph receptors, producing: | HPA Effect | Hexarelin | GHRP-2 | Ipamorelin | | --- | --- | --- | --- | | Cortisol elevation | **+30-50%** | +15-25% | Minimal | | ACTH elevation | **Meaningful** | Minor | Negligible | | Prolactin elevation | **Pronounced** | Modest | Minimal | This is why hexarelin is **the least suitable GHRP for chronic daily use** and the most suitable for short aggressive cycles (4-6 weeks) where peak anabolic effect is prioritized and cumulative HPA exposure is limited. ### Faster GHS-R1a Desensitization Chronic hexarelin administration produces **more rapid receptor desensitization** than GHRP-2 or ipamorelin. Clinical data documents a measurable attenuation of GH response within 4-8 weeks of continuous daily dosing, whereas other GHRPs maintain responsiveness for 12+ weeks before cycling is strictly needed ([Imbimbo 1994]). This pharmacodynamic quirk drives a shorter cycling recommendation - typically 4-6 weeks on with 2-4 weeks off, or a low-dose (<100 mcg) maintenance if continuous use is required. ### Synergy with GHRH Despite its selectivity issues, hexarelin retains the classical GHS x GHRH synergy. Combined with GHRH analogs (sermorelin, CJC-1295 no-DAC), hexarelin produces GH pulse amplification of **3-5x** versus either compound alone - the same multiplier observed with other GHRPs ([Bowers 1991]). The practical question with hexarelin+GHRH is whether the greater peak GH pulse amplitude compensates for the greater HPA cross-reactivity. In short-duration anabolic phases, usually yes; in chronic protocols, usually no. ### Appetite Effects Hexarelin is intermediate in its appetite-stimulating effects - more than ipamorelin (which is minimal), less than GHRP-6 (which is pronounced), and roughly equivalent to GHRP-2. ### Overview Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue with the sequence **His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2**. It is structurally similar to GHRP-6 and GHRP-2 but features a 2-methyl-substituted tryptophan residue that produces **significantly higher GH-releasing potency on a per-molecule basis** — reportedly the most potent of the classical GHRPs when measured by peak GH pulse amplitude at equivalent molar doses ([Imbimbo et al., 1994]). This potency comes with a tradeoff: hexarelin produces **the most pronounced cortisol, prolactin, and ACTH elevations of any commonly-used GHS compound**. Where GHRP-2 and GHRP-6 cause modest (+15-25%) cortisol elevations, hexarelin can produce cortisol increases of +30-50% above baseline in the 60-90 minute post-injection window, along with meaningful ACTH stimulation that is not seen with the more selective analogs. Chronic daily use also produces **faster GHS-R1a receptor desensitization** than other GHRPs, making hexarelin better suited to short aggressive cycles than to continuous long-term protocols. Beyond its GH-axis effects, hexarelin has generated significant research interest for **cardioprotective properties** mediated through CD36 receptor binding — a mechanism independent of GHS-R1a. Preclinical studies have documented reduced infarct size following ischemia-reperfusion insult, improved cardiac contractility, and beneficial effects on cardiac remodeling in animal models ([Torsello et al., 2003]). Clinical translation to human cardiac therapy has not occurred, but the cardiac research niche distinguishes hexarelin from other GHRPs. Hexarelin has been studied extensively in clinical trials for **pediatric and adult GH deficiency diagnostic testing**, particularly in European centers, where single IV boluses produce reliable and discriminating GH responses ([Loche et al., 1995]; [Arvat et al., 1995]). It is not FDA-approved and has no broadly approved therapeutic indication. Research-grade use is via SC injection, typically 100-200 mcg 1-3 times daily, with shorter cycling (4-6 weeks on / 2-4 weeks off) more commonly recommended than with other GHRPs due to the faster receptor desensitization profile. ### Potential Research Fields GH deficiency Cardiac ischemia Heart failure Body composition ## Chemical Information IUPAC Name His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2 CAS Number 140703-51-1 Molecular Formula C47H58N12O6 Molecular Mass 887.05 g/mol Image: Hexarelin molecular structure (https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/9888045/PNG?image_size=300x300) View on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/9888045 Amino Acid Sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 ## Dosing & Protocols ### Unlock the dosing protocols Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser. - Dose, route, how often and how long - A titration schedule - Beginner, intermediate and advanced protocols - Reconstitution and handling notes You also get the free peptide cheat sheet by email. Unsubscribe anytime. Have an account? Sign in (https://www.bodyhackguide.co/auth) ## Research ### Unlock the research summary - A summary of the key research - Safety and side effects - A link to the PubMed results ## Interactions ### Interaction Matrix ### Contraindications Hexarelin is contraindicated or requires strict caution in: - **Active malignancy** — particularly hormone-responsive cancers; IGF-1 elevation theoretical risk - **Strong family history of GH-axis sensitive cancers** — specialist supervision required - **Pregnancy and lactation** — no established safety data - **Known hypersensitivity** to hexarelin or related hexapeptides - **Severe untreated obstructive sleep apnea** — stabilize with CPAP first - **Acute critical illness** — GH-axis stimulation inappropriate during sepsis, post-surgical recovery, multiple trauma, respiratory failure - **Diabetic ketoacidosis or severe uncontrolled diabetes** — resolve metabolic state first - **Active proliferative retinopathy** — relative contraindication - **Hypothalamic-pituitary disease with untreated adrenal insufficiency** — hexarelin's HPA effects may be unreliable in this context - **Active Cushing's syndrome or elevated baseline cortisol** — hexarelin adds meaningfully to HPA load - **Prolactinoma or clinically significant hyperprolactinemia** — hexarelin's prolactin elevation could complicate management - **Active anxiety disorder, panic disorder, or acute stress reaction** — HPA axis effects can worsen symptoms **Relative cautions specific to hexarelin:** - Borderline glucose / HbA1c — insulin sensitivity effects appear faster with hexarelin than with cleaner GHS compounds - Mood instability, depression, or insomnia — the HPA axis effects may contribute to worsening - Cardiovascular disease (despite preclinical CD36 data) — the acute blood pressure and cortisol effects are not neutral in this population; clinical cardiac use has not been validated - Concurrent glucocorticoid therapy — pharmacodynamic interference; additive HPA load - Strong family history of colon polyps — baseline colonoscopy before GH-axis intervention - Users who have had previous difficulty tolerating GHS compounds — hexarelin is the most HPA-affecting; ipamorelin is much cleaner **Drug interactions:** - **Glucocorticoids:** Reduced GH response; additive HPA load - **Stimulants (high caffeine, pre-workouts):** Additive sympathomimetic and HPA load - **MAO inhibitors:** Theoretical interaction; specialist oversight - **GLP-1 agonists during weight loss phase:** Opposing appetite signals - **Thyroid hormones:** GH-axis effects can alter thyroid needs - **Exogenous HGH:** Pharmacologically counterproductive **Discontinuation triggers:** - Cortisol elevation >30% above baseline at follow-up labs - ACTH elevation beyond reference range - Prolactin elevation beyond reference range - New or worsened anxiety, insomnia, or mood changes - Fasting glucose persistently >110 mg/dL - Central (abdominal) weight gain beyond caloric intake explanation — suggesting cortisol-driven body composition change - Persistent joint pain or peripheral edema - Worsening sleep apnea - Any cardiovascular symptoms Research Disclaimer This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds. No listings found for Hexarelin. ### Sign in to leave a review Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with Hexarelin. ### Related Compounds View All (https://www.bodyhackguide.co/wiki) ### CJC-1295 (Mod GRF 1-29) Growth Hormone / IGF-1 Axis Preclinical CJC-1295 without DAC (also called Modified GRF 1-29 or MOD-GRF 1-29) is a 30-amino-acid analog of the first 29 residues of endogenous Growth Hormone Releasing Hormone (GHRH), with four strategic substitutions (D-Ala² for DPP-4 resistance, Gln⁸, Ala¹⁵, Leu²⁷) that extend its plasma half-life from <2 minutes (native GHRH) to ~30 minutes. t½ ~30 minutes (without DAC / MOD-GRF 1-29); ~6-8 days (with DAC, due to covalent albumin binding) Without DAC: 100-300 mcg subcutaneous 1-3x daily (typically pre-bedtime); With DAC: 1000-2000 mcg subcutaneous once weekly 29 PubMed View Profile https://www.bodyhackguide.co/compound/cjc-1295 ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis Preclinical / Research peptide CJC-1295 with DAC is the long-acting variant of CJC-1295. t½ ~6-8 days (DAC-bound albumin depot) 1000-2000 mcg (1-2 mg) per week Preclinical View Profile https://www.bodyhackguide.co/compound/cjc-1295-with-dac ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis Phase 2 CJC-1295 with DAC (Drug Affinity Complex) is a modified form of CJC-1295 that incorporates a maleimidopropionic acid (MPA) reactive group at the C-terminus. t½ 6–8 days (due to albumin binding via DAC) 1,000–2,000 mcg (1–2 mg) per injection Preclinical View Profile https://www.bodyhackguide.co/compound/cjc-1295-dac ### GHRP-2 Growth Hormone / IGF-1 Axis Phase 2 GHRP-2 (growth hormone-releasing peptide-2), also known as pralmorelin and KP-102, is a synthetic hexapeptide growth hormone secretagogue that was among the first GHRPs developed in the seminal research of Cyril Bowers and colleagues at Tulane University in the late 1980s and early 1990s. t½ ~15-30 minutes 100–300 mcg per injection 212 PubMed View Profile https://www.bodyhackguide.co/compound/ghrp-2 ### GHRP-6 Growth Hormone / IGF-1 Axis Phase 2 GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 that binds the ghrelin receptor (GHS-R1a) to stimulate endogenous growth hormone release. t½ ~20–30 minutes 100–300 mcg per injection 156 PubMed View Profile https://www.bodyhackguide.co/compound/ghrp-6 ### IGF-1 LR3 Growth Hormone / IGF-1 Axis Phase 2 IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of human insulin-like growth factor 1 modified at two positions to dramatically extend its serum half-life and amplify its tissue bioactivity compared to native IGF-1. t½ 20-30 hours (community/vendor estimate; no published human PK study of IGF-1 LR3) vs ~12 minutes for native IGF-1 20-80 mcg per day 40 PubMed View Profile https://www.bodyhackguide.co/compound/igf-1-lr3 ### Side-by-Side Comparisons All Comparisons (https://www.bodyhackguide.co/compare) Hexarelin vs Ipamorelin: https://www.bodyhackguide.co/compare/hexarelin-vs-ipamorelin View Full Dosage Guide → Protocols, calculator & safety for Hexarelin https://www.bodyhackguide.co/guides/dosage/hexarelin ### Related Articles All Posts (https://www.bodyhackguide.co/blog) #### The Complete Peptide Reconstitution Guide (2026): Ratios, Math, and Common Mistakes The master reconstitution reference for 17 peptides. BAC vs SWFI vs acetic acid, mg/mL targets, IU math on U100 syringes, storage and stability by peptide class, sterile technique, and the mistakes that destroy $60 vials. Includes worked examples for BPC-157, TB-500, GHK-Cu, semaglutide, tirzepatide, CJC-1295, ipamorelin, sermorelin, GHRPs, Melanotan II, PT-141, oxytocin, Semax, Selank, DSIP, and epithalon. 4/21/2026 https://www.bodyhackguide.co/blog/complete-peptide-reconstitution-guide-2026 ### Price check No vendor listings yet See the vendor scorecard (https://www.bodyhackguide.co/vendors/scorecard) ### Research Score 61 14 PubMed results ### Quality Indicators Data Completeness 88% Description Mechanism of Action Chemical Data Dosing Protocols Safety Profile PubMed Results Interactions Vendor Listings Research Volume 14 PubMed results ### Quick Facts Half-Life ~55 minutes (IV, per Imbimbo 1994) Molecular Weight 887.05 g/mol Administration Subcutaneous, Intramuscular CAS Number 140703-51-1 Trial Phase Phase 2 ### Safety Profile Moderate Risk Common Side Effects - • Cortisol and prolactin elevation - • Water retention - • Fatigue - • Hunger Stop Use If - Active malignancy - Uncontrolled cardiovascular disease - Cushing's syndrome Research Disclaimer This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use. ## Frequently Asked Questions What is hexarelin and how does it work? Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue that binds two distinct receptors: GHS-R1a (the ghrelin receptor - drives endogenous GH release) and CD36 (a scavenger receptor on cardiomyocytes - drives cardioprotective effects). It is the most potent of the classical GHRPs on a per-molecule basis, producing the highest peak GH pulse amplitude at equivalent doses. However, this potency comes with the strongest HPA axis cross-reactivity among GHRPs - meaningful cortisol, prolactin, and ACTH elevation - and the fastest GHS-R1a receptor desensitization. It is not FDA-approved; research use is typically SC injection 100-200 mcg 1-2 times daily in short (4-6 week) cycles. How is hexarelin different from GHRP-2 or ipamorelin? All three are GHS-R1a agonists but with different selectivity profiles. Hexarelin has the highest GH-release potency but the highest HPA cross-reactivity (cortisol +30-50%, meaningful ACTH and prolactin elevation) and fastest receptor desensitization. GHRP-2 has strong GH potency with modest HPA effects (+15-25% cortisol). Ipamorelin has good GH potency with minimal HPA effects (negligible cortisol, prolactin, ACTH impact). Practical implication: hexarelin for short aggressive 4-6 week phases where peak GH pulse matters; GHRP-2 for medium-duration use; ipamorelin for chronic clean daily use. Hexarelin is uniquely able to bind CD36, which drives its cardioprotective research interest - a property neither GHRP-2 nor ipamorelin share. What is the best hexarelin dosage? Standard SC protocol is 100-200 mcg per injection, 1-2 times daily (pre-breakfast and pre-bed), cycled 4-6 weeks on with 2-4 weeks off. Beginners start at 100 mcg once daily (pre-bed only) to assess tolerance before escalating. Intermediate users run 150-200 mcg twice daily. The single-injection ceiling is approximately 200 mcg - above this, receptor saturation prevents additional GH release while cortisol continues to rise proportionally. Hexarelin should not be used continuously longer than 6 weeks because receptor desensitization attenuates GH response and cumulative cortisol/prolactin exposure becomes meaningful. Always dose fasted (2-3 hours after last meal) to avoid glucose/insulin-driven somatostatin blunting of GH release. Does hexarelin raise cortisol a lot? Yes - hexarelin produces the most pronounced cortisol elevation of any commonly-used GHS compound, typically +30-50% above baseline in the 60-90 minute post-injection window, versus +15-25% for GHRP-2/GHRP-6 and negligible effects for ipamorelin. Hexarelin also meaningfully elevates ACTH, which other GHRPs do not. Per single dose, this is usually clinically trivial in healthy users. Cumulative chronic exposure matters more - which is why hexarelin is recommended for short 4-6 week cycles rather than continuous long-term use. Users with baseline anxiety, HPA axis concerns, insomnia, or mood disorders should use ipamorelin instead of hexarelin. Cortisol monitoring on labs (baseline and end-of-cycle) is important for hexarelin specifically. What are hexarelin cardiac effects? Hexarelin binds CD36, a scavenger receptor expressed on cardiomyocytes and macrophages. Preclinical research in animal models documents reduced infarct size following ischemia-reperfusion insult, improved ventricular contractility in cardiomyopathy models, anti-inflammatory effects at vascular endothelium, and favorable cardiac remodeling after experimental myocardial infarction (Torsello 2003 and subsequent work). These effects are mechanistically independent of the GH/IGF-1 axis - hexarelin produces cardiac protection even when GHS-R1a is blocked. Clinical translation to human cardiac therapy has not occurred; no validated cardiac indication exists. The cardiac research interest is genuine but doesn't support self-experimentation in cardiovascular disease - specialist-supervised research protocols only. Can hexarelin be stacked with other peptides? Yes, selectively. The most pharmacologically significant stack is hexarelin + GHRH analog (sermorelin, CJC-1295 no-DAC, or tesamorelin) in the same injection - produces the largest GH pulses of any common peptide combination, appropriate for short 4-6 week intensive phases. Hexarelin also stacks well with BPC-157 and TB-500 for tissue repair during aggressive training cycles, and with testosterone replacement for additive anabolic effects. AVOID stacking hexarelin with other GHS-R1a agonists (GHRP-2, GHRP-6, ipamorelin, MK-677) - they are mechanistically redundant. Also avoid stacking with glucocorticoids, high-dose stimulants, or GLP-1 agonists during active weight loss phases. Hexarelin is the GHS compound most sensitive to bad stacking choices because of the HPA cross-reactivity. What are the side effects of hexarelin? Common effects: pronounced facial flushing and warmth post-injection (stronger than other GHRPs), injection site reactions, cortisol elevation (+30-50% above baseline for 60-90 min), prolactin elevation, intermediate appetite stimulation, and vivid dreams with bedtime dosing. Less common: headache (more frequent than with other GHRPs), mild nausea, transient hypotension with IV administration, fluid retention in first weeks, insulin sensitivity reduction with chronic use. The HPA axis effects are the distinguishing hexarelin signature - ACTH elevation that other GHRPs do not cause. Long-term theoretical concerns include cumulative cortisol exposure contributing to HPA dysregulation, insulin resistance, and sustained IGF-1 elevation. Short cycling (4-6 weeks) minimizes these concerns significantly. Is hexarelin legal? Hexarelin is not FDA-approved for any indication in the United States. It has been studied in European clinical trials for GH deficiency diagnostic testing and cardiac research. Research-grade hexarelin is sold through peptide research suppliers under research-only classification. Users should understand this legal context, source from vendors with third-party purity testing, and ideally work with a practitioner familiar with peptide therapy. Some 503B compounding pharmacies include hexarelin in their offerings for physician-supervised off-label use, though it's less commonly compounded than ipamorelin or GHRP-2. See our best vendors guide (https://www.bodyhackguide.co/guides/best-vendors-2026) for reliable sources and peptide-friendly clinical practices. Why do hexarelin cycles need to be shorter than other GHRPs? Hexarelin produces more rapid GHS-R1a receptor desensitization than GHRP-2, GHRP-6, or ipamorelin. Within 4-8 weeks of continuous daily dosing, GH response measurably attenuates - you get smaller GH pulses for the same dose. Dose escalation to overcome this attenuation disproportionately increases cortisol and prolactin exposure rather than restoring GH output. The pharmacologically sensible response is to cycle: 4-6 weeks on, then 2-4 weeks off, allowing the receptor to resensitize. Other GHRPs maintain responsiveness for 12+ weeks before cycling is strictly needed. This cycling requirement is why hexarelin is better positioned as a situational short-cycle tool than as a chronic daily compound - ipamorelin or low-dose GHRP-2 are better for continuous long-term GH support. Should I use hexarelin or ipamorelin for bodybuilding? Most modern peptide protocols favor ipamorelin for the majority of bodybuilding use cases because: (1) it can be used continuously for 12+ weeks without meaningful receptor desensitization, (2) it has minimal HPA cross-reactivity, (3) it has minimal appetite effect (useful during cutting), and (4) its longer half-life (~2 hours vs hexarelin's ~55 minutes) provides more sustained coverage. Hexarelin has a legitimate role in short 4-6 week intensive anabolic phases where maximum peak GH pulse matters more than cortisol cleanliness - typically stacked with CJC-1295 no-DAC and testosterone replacement. After a hexarelin phase, transition back to ipamorelin for maintenance and cut phases. Using hexarelin continuously for bodybuilding is a common mistake that produces diminishing GH returns and accumulating cortisol exposure. See ipamorelin (https://www.bodyhackguide.co/compound/ipamorelin) for detailed use-case comparison. ## Research Tools ### Peptide Calculator Reconstitution & syringe units https://www.bodyhackguide.co/tools/reconstitution ### Reconstitution Guide How to mix, step by step https://www.bodyhackguide.co/guides/how-to-reconstitute-peptides ### Nasal Spray Calc mL per actuation https://www.bodyhackguide.co/tools/intranasal ### Half-Life Visualizer Decay curves https://www.bodyhackguide.co/tools/halflife ## Related Compounds ### CJC-1295 (Mod GRF 1-29) Growth Hormone / IGF-1 Axis Preclinical ### CJC-1295 with DAC ### CJC-1295 with DAC Growth Hormone / IGF-1 Axis Phase 2 ### GHRP-2 Growth Hormone / IGF-1 Axis Phase 2 ### GHRP-6 Growth Hormone / IGF-1 Axis Phase 2 ### IGF-1 LR3 Growth Hormone / IGF-1 Axis Phase 2 ## Side-by-Side Comparisons Compare Hexarelin head-to-head: mechanism, half-life, dosing, safety, and vendor prices. Free 2026 Peptide Cheat Sheet (PDF) 38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers. Download Free (https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download) ### Need bloodwork before starting? Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount. Image: BodyHackGuide (https://www.bodyhackguide.co/assets/bodyhackguide-logo-DOzZNUyh.webp) ### BodyHackGuide Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide #### Explore - Compare prices: https://www.bodyhackguide.co/compare - Vendors: https://www.bodyhackguide.co/vendors - Deals: https://www.bodyhackguide.co/deals - Coupons: https://www.bodyhackguide.co/coupons - Nootropics: https://www.bodyhackguide.co/nootropics - Brain health: https://www.bodyhackguide.co/brain-health - Blog: https://www.bodyhackguide.co/blog - Guides: https://www.bodyhackguide.co/guides #### Tools - Reconstitution: https://www.bodyhackguide.co/tools/reconstitution - Half-life visualizer: https://www.bodyhackguide.co/tools/halflife - COA reader: https://www.bodyhackguide.co/tools/coa - Cost calculator: https://www.bodyhackguide.co/tools/cost-calculator - Stack builder: https://www.bodyhackguide.co/stack-builder - All tools: https://www.bodyhackguide.co/tools #### Trust & vendors - Vendor directory: https://www.bodyhackguide.co/vendors - Trust scorecard: https://www.bodyhackguide.co/vendors/scorecard - Vendor trust badge: https://www.bodyhackguide.co/vendors/get-vetted - Scoring methodology: https://www.bodyhackguide.co/vendors/methodology - Peptide cheat sheet: https://www.bodyhackguide.co/guides/peptide-cheat-sheet-download #### Company - About: https://www.bodyhackguide.co/about - Affiliate disclosure: https://www.bodyhackguide.co/affiliate-disclosure - Editorial standards: https://www.bodyhackguide.co/editorial-standards - Creators: https://www.bodyhackguide.co/creators - Coaches: https://www.bodyhackguide.co/coaches - 1-on-1 coaching: https://www.bodyhackguide.co/coaching - Privacy: https://www.bodyhackguide.co/privacy - Terms: https://www.bodyhackguide.co/terms - Full site directory: https://www.bodyhackguide.co/site-directory **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology), and we earn a commission from purchases made through some of our links at no extra cost to you. Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. · Terms (https://www.bodyhackguide.co/terms) · Privacy (https://www.bodyhackguide.co/privacy) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Compounds", "item": "https://www.bodyhackguide.co/compare" }, { "@type": "ListItem", "position": 3, "name": "Hexarelin" } ] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Hexarelin", "description": "Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. It is structurally similar to GHRP-6 and GHRP-2 but features a 2-methyl-substituted tryptophan residue that produces significantly higher GH-releasing potency on a per-molecule basis — reportedly the most potent of the classical GHRPs when measured by peak GH pulse amplitude at equivalent molar doses ([Imbimbo et al., 1994]). This potency comes with a tradeoff: hexarelin produces the most pronounced cortisol, prolactin, and ACTH elevations of any commonly-used GHS compound. Where GHRP-2 and GHRP-6 cause modest (+15-25%) cortisol elevations, hexarelin can produce cortisol increases of +30-50% above baseline in the 60-90 minute post-injection window, along with meaningful ACTH stimulation that is not seen with the more selective analogs. Chronic daily use also produces faster GHS-R1a receptor desensitization than other GHRPs, making hexarelin better suited to short aggressive cycles than to continuous long-term protocols. Beyond its GH-axis effects, hexarelin has generated significant research interest for cardioprotective properties mediated through CD36 receptor binding — a mechanism independent of GHS-R1a. Preclinical studies have documented reduced infarct size following ischemia-reperfusion insult, improved cardiac contractility, and beneficial effects on cardiac remodeling in animal models ([Torsello et al., 2003]). Clinical translation to human cardiac therapy has not occurred, but the cardiac research niche distinguishes hexarelin from other GHRPs. Hexarelin has been studied extensively in clinical trials for pediatric and adult GH deficiency diagnostic testing, particularly in European centers, where single IV boluses produce reliable and discriminating GH responses ([Loche et al., 1995]; [Arvat et al., 1995]). It is not FDA-approved and has no broadly approved therapeutic indication. Research-grade use is via SC injection, typically 100-200 mcg 1-3 times daily, with shorter cycling (4-6 weeks on / 2-4 weeks off) more commonly recommended than with other GHRPs due to the faster receptor desensitization profile.", "lastReviewed": "2026-05-04T11:34:27.93+00:00", "url": "https://www.bodyhackguide.co/compound/hexarelin", "author": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "reviewedBy": { "@type": "Person", "name": "BioChonch", "url": "https://www.bodyhackguide.co/about", "jobTitle": "Founder & Lead Researcher", "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher" ], "worksFor": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" } }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co" }, "mainContentOfPage": { "@type": "WebPageElement", "cssSelector": "main" }, "about": { "@type": "Drug", "name": "Hexarelin", "alternateName": [ "Examorelin" ], "description": "Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. It is structurally similar to GHRP-6 and GHRP-2 but features a 2-methyl-substituted tryptophan residue that produces significantly higher GH-releasing potency on a per-molecule basis — reportedly the most potent of the classical GHRPs when measured by peak GH pulse amplitude at equivalent molar doses ([Imbimbo et al., 1994]). This potency comes with a tradeoff: hexarelin produces the most pronounced cortisol, prolactin, and ACTH elevations of any commonly-used GHS compound. Where GHRP-2 and GHRP-6 cause modest (+15-25%) cortisol elevations, hexarelin can produce cortisol increases of +30-50% above baseline in the 60-90 minute post-injection window, along with meaningful ACTH stimulation that is not seen with the more selective analogs. Chronic daily use also produces faster GHS-R1a receptor desensitization than other GHRPs, making hexarelin better suited to short aggressive cycles than to continuous long-term protocols. Beyond its GH-axis effects, hexarelin has generated significant research interest for cardioprotective properties mediated through CD36 receptor binding — a mechanism independent of GHS-R1a. Preclinical studies have documented reduced infarct size following ischemia-reperfusion insult, improved cardiac contractility, and beneficial effects on cardiac remodeling in animal models ([Torsello et al., 2003]). Clinical translation to human cardiac therapy has not occurred, but the cardiac research niche distinguishes hexarelin from other GHRPs. Hexarelin has been studied extensively in clinical trials for pediatric and adult GH deficiency diagnostic testing, particularly in European centers, where single IV boluses produce reliable and discriminating GH responses ([Loche et al., 1995]; [Arvat et al., 1995]). It is not FDA-approved and has no broadly approved therapeutic indication. Research-grade use is via SC injection, typically 100-200 mcg 1-3 times daily, with shorter cycling (4-6 weeks on / 2-4 weeks off) more commonly recommended than with other GHRPs due to the faster receptor desensitization profile.", "activeIngredient": "Hexarelin", "administrationRoute": "Subcutaneous, Intramuscular", "mechanismOfAction": "Dual Receptor Pharmacology Hexarelin is distinguished from other GHRPs by its activity at two distinct receptors: GHS-R1a (primary - GH release) Like all GHRPs, hexarelin binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons: Gq/11 coupling phospholipase C IP3/Ca release GH granule exocytosis Hypothalamic arcuate nucleus activation endogenous GHRH amplification Partial somatostatin antagonism removes the GH-release ceiling The GH-release potency of hexarelin exceeds GHRP-2 and GHRP-6 at equivalent molar doses. Peak GH elevations of ~50-70 ng/mL are achievable with modest (1-2 mcg/kg) IV bolus doses. CD36 (secondary - cardioprotective) Hexarelin also binds CD36 - a scavenger receptor expressed on cardiomyocytes, macrophages, and vascular endothelium. CD36 binding is not a property of GHRP-2 or ipamorelin; it is a distinctive hexarelin feature and drives the cardioprotective effects: Reduced infarct size in experimental ischemia-reperfusion ([Torsello 2003]) Improved ventricular contractility in cardiomyopathy models Anti-inflammatory effects at vascular endothelium Favorable cardiac remodeling following experimental MI The CD36 pathway is mechanistically independent of the GH/IGF-1 axis - hexarelin produces cardiac protection even when co-administered with GHS-R1a antagonists that block the GH-release signal. This has generated ongoing research interest in ghrelin-agonist cardioprotection as a discrete therapeutic avenue. HPA Axis Cross-Reactivity (The Cost of Potency) The 2-methyl-tryptophan modification that amplifies GH-release potency also amplifies binding at pituitary corticotroph receptors, producing: This is why hexarelin is the least suitable GHRP for chronic daily use and the most suitable for short aggressive cycles (4-6 weeks) where peak anabolic effect is prioritized and cumulative HPA exposure is limited. Faster GHS-R1a Desensitization Chronic hexarelin administration produces more rapid receptor desensitization than GHRP-2 or ipamorelin. Clinical data documents a measurable attenuation of GH response within 4-8 weeks of continuous daily dosing, whereas other GHRPs maintain responsiveness for 12+ weeks before cycling is strictly needed ([Imbimbo 1994]). This pharmacodynamic quirk drives a shorter cycling recommendation - typically 4-6 weeks on with 2-4 weeks off, or a low-dose (<100 mcg) maintenance if continuous use is required. Synergy with GHRH Despite its selectivity issues, hexarelin retains the classical GHS x GHRH synergy. Combined with GHRH analogs (sermorelin, CJC-1295 no-DAC), hexarelin produces GH pulse amplification of 3-5x versus either compound alone - the same multiplier observed with other GHRPs ([Bowers 1991]). The practical question with hexarelin+GHRH is whether the greater peak GH pulse amplitude compensates for the greater HPA cross-reactivity. In short-duration anabolic phases, usually yes; in chronic protocols, usually no. Appetite Effects Hexarelin is intermediate in its appetite-stimulating effects - more than ipamorelin (which is minimal), less than GHRP-6 (which is pronounced), and roughly equivalent to GHRP-2.", "legalStatus": "Not approved for human use (research chemical)", "warning": "For research purposes only. Not for human consumption." } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is hexarelin and how does it work?", "acceptedAnswer": { "@type": "Answer", "text": "Hexarelin (also called examorelin) is a potent synthetic hexapeptide growth hormone secretagogue that binds two distinct receptors: GHS-R1a (the ghrelin receptor - drives endogenous GH release) and CD36 (a scavenger receptor on cardiomyocytes - drives cardioprotective effects). It is the most potent of the classical GHRPs on a per-molecule basis, producing the highest peak GH pulse amplitude at equivalent doses. However, this potency comes with the strongest HPA axis cross-reactivity among GHRPs - meaningful cortisol, prolactin, and ACTH elevation - and the fastest GHS-R1a receptor desensitization. It is not FDA-approved; research use is typically SC injection 100-200 mcg 1-2 times daily in short (4-6 week) cycles." } }, { "@type": "Question", "name": "How is hexarelin different from GHRP-2 or ipamorelin?", "acceptedAnswer": { "@type": "Answer", "text": "All three are GHS-R1a agonists but with different selectivity profiles. Hexarelin has the highest GH-release potency but the highest HPA cross-reactivity (cortisol +30-50%, meaningful ACTH and prolactin elevation) and fastest receptor desensitization. GHRP-2 has strong GH potency with modest HPA effects (+15-25% cortisol). Ipamorelin has good GH potency with minimal HPA effects (negligible cortisol, prolactin, ACTH impact). Practical implication: hexarelin for short aggressive 4-6 week phases where peak GH pulse matters; GHRP-2 for medium-duration use; ipamorelin for chronic clean daily use. Hexarelin is uniquely able to bind CD36, which drives its cardioprotective research interest - a property neither GHRP-2 nor ipamorelin share." } }, { "@type": "Question", "name": "What is the best hexarelin dosage?", "acceptedAnswer": { "@type": "Answer", "text": "Standard SC protocol is 100-200 mcg per injection, 1-2 times daily (pre-breakfast and pre-bed), cycled 4-6 weeks on with 2-4 weeks off. Beginners start at 100 mcg once daily (pre-bed only) to assess tolerance before escalating. Intermediate users run 150-200 mcg twice daily. The single-injection ceiling is approximately 200 mcg - above this, receptor saturation prevents additional GH release while cortisol continues to rise proportionally. Hexarelin should not be used continuously longer than 6 weeks because receptor desensitization attenuates GH response and cumulative cortisol/prolactin exposure becomes meaningful. Always dose fasted (2-3 hours after last meal) to avoid glucose/insulin-driven somatostatin blunting of GH release." } }, { "@type": "Question", "name": "Does hexarelin raise cortisol a lot?", "acceptedAnswer": { "@type": "Answer", "text": "Yes - hexarelin produces the most pronounced cortisol elevation of any commonly-used GHS compound, typically +30-50% above baseline in the 60-90 minute post-injection window, versus +15-25% for GHRP-2/GHRP-6 and negligible effects for ipamorelin. Hexarelin also meaningfully elevates ACTH, which other GHRPs do not. Per single dose, this is usually clinically trivial in healthy users. Cumulative chronic exposure matters more - which is why hexarelin is recommended for short 4-6 week cycles rather than continuous long-term use. Users with baseline anxiety, HPA axis concerns, insomnia, or mood disorders should use ipamorelin instead of hexarelin. Cortisol monitoring on labs (baseline and end-of-cycle) is important for hexarelin specifically." } }, { "@type": "Question", "name": "What are hexarelin cardiac effects?", "acceptedAnswer": { "@type": "Answer", "text": "Hexarelin binds CD36, a scavenger receptor expressed on cardiomyocytes and macrophages. Preclinical research in animal models documents reduced infarct size following ischemia-reperfusion insult, improved ventricular contractility in cardiomyopathy models, anti-inflammatory effects at vascular endothelium, and favorable cardiac remodeling after experimental myocardial infarction (Torsello 2003 and subsequent work). These effects are mechanistically independent of the GH/IGF-1 axis - hexarelin produces cardiac protection even when GHS-R1a is blocked. Clinical translation to human cardiac therapy has not occurred; no validated cardiac indication exists. The cardiac research interest is genuine but doesn't support self-experimentation in cardiovascular disease - specialist-supervised research protocols only." } }, { "@type": "Question", "name": "Can hexarelin be stacked with other peptides?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, selectively. The most pharmacologically significant stack is hexarelin + GHRH analog (sermorelin, CJC-1295 no-DAC, or tesamorelin) in the same injection - produces the largest GH pulses of any common peptide combination, appropriate for short 4-6 week intensive phases. Hexarelin also stacks well with BPC-157 and TB-500 for tissue repair during aggressive training cycles, and with testosterone replacement for additive anabolic effects. AVOID stacking hexarelin with other GHS-R1a agonists (GHRP-2, GHRP-6, ipamorelin, MK-677) - they are mechanistically redundant. Also avoid stacking with glucocorticoids, high-dose stimulants, or GLP-1 agonists during active weight loss phases. Hexarelin is the GHS compound most sensitive to bad stacking choices because of the HPA cross-reactivity." } }, { "@type": "Question", "name": "What are the side effects of hexarelin?", "acceptedAnswer": { "@type": "Answer", "text": "Common effects: pronounced facial flushing and warmth post-injection (stronger than other GHRPs), injection site reactions, cortisol elevation (+30-50% above baseline for 60-90 min), prolactin elevation, intermediate appetite stimulation, and vivid dreams with bedtime dosing. Less common: headache (more frequent than with other GHRPs), mild nausea, transient hypotension with IV administration, fluid retention in first weeks, insulin sensitivity reduction with chronic use. The HPA axis effects are the distinguishing hexarelin signature - ACTH elevation that other GHRPs do not cause. Long-term theoretical concerns include cumulative cortisol exposure contributing to HPA dysregulation, insulin resistance, and sustained IGF-1 elevation. Short cycling (4-6 weeks) minimizes these concerns significantly." } }, { "@type": "Question", "name": "Is hexarelin legal?", "acceptedAnswer": { "@type": "Answer", "text": "Hexarelin is not FDA-approved for any indication in the United States. It has been studied in European clinical trials for GH deficiency diagnostic testing and cardiac research. Research-grade hexarelin is sold through peptide research suppliers under research-only classification. Users should understand this legal context, source from vendors with third-party purity testing, and ideally work with a practitioner familiar with peptide therapy. Some 503B compounding pharmacies include hexarelin in their offerings for physician-supervised off-label use, though it's less commonly compounded than ipamorelin or GHRP-2. See our best vendors guide for reliable sources and peptide-friendly clinical practices." } }, { "@type": "Question", "name": "Why do hexarelin cycles need to be shorter than other GHRPs?", "acceptedAnswer": { "@type": "Answer", "text": "Hexarelin produces more rapid GHS-R1a receptor desensitization than GHRP-2, GHRP-6, or ipamorelin. Within 4-8 weeks of continuous daily dosing, GH response measurably attenuates - you get smaller GH pulses for the same dose. Dose escalation to overcome this attenuation disproportionately increases cortisol and prolactin exposure rather than restoring GH output. The pharmacologically sensible response is to cycle: 4-6 weeks on, then 2-4 weeks off, allowing the receptor to resensitize. Other GHRPs maintain responsiveness for 12+ weeks before cycling is strictly needed. This cycling requirement is why hexarelin is better positioned as a situational short-cycle tool than as a chronic daily compound - ipamorelin or low-dose GHRP-2 are better for continuous long-term GH support." } }, { "@type": "Question", "name": "Should I use hexarelin or ipamorelin for bodybuilding?", "acceptedAnswer": { "@type": "Answer", "text": "Most modern peptide protocols favor ipamorelin for the majority of bodybuilding use cases because: (1) it can be used continuously for 12+ weeks without meaningful receptor desensitization, (2) it has minimal HPA cross-reactivity, (3) it has minimal appetite effect (useful during cutting), and (4) its longer half-life (~2 hours vs hexarelin's ~55 minutes) provides more sustained coverage. Hexarelin has a legitimate role in short 4-6 week intensive anabolic phases where maximum peak GH pulse matters more than cortisol cleanliness - typically stacked with CJC-1295 no-DAC and testosterone replacement. After a hexarelin phase, transition back to ipamorelin for maintenance and cut phases. Using hexarelin continuously for bodybuilding is a common mistake that produces diminishing GH returns and accumulating cortisol exposure. See ipamorelin for detailed use-case comparison." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 124+ compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```